Development of Immunologic Assays to Measure Response in Horses Vaccinated with Xenogeneic Plasmid DNA Encoding Human Tyrosinase

Journal of Equine Veterinary Science

Volumn 32, Issue 10, 2012, Pages 607-615

  Lembcke, Luis M ^a   Kania, Stephen A ^a   Blackford, James T ^a   Trent, Dianne J ^a   Odoi, Agricola ^a   Grosenbaugh, Deborah A ^b   Fraser, Darrilyn G ^b   Leard, Timothy ^b   Phillips, Jeffrey C ^c  

^a UNIVERSITY OF TENNESSEE   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c LINCOLN MEMORIAL UNIVERSITY   (United States)

Author keywords

Horse; Immune response; Immunotherapy; Melanoma; Tyrosinase; Vaccine

Indexed keywords

CANIS FAMILIARIS; EQUIDAE;

EID: 84867710980     PISSN: 07370806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jevs.2012.02.011     Document Type: Article

References (43)

1. Sundberg J.P., Burnstein T., Page E.H., Kirkham W.W., Robinson F.R. Neoplasms of equidae. J Am Vet Med Assoc 1977, 170:150-152.
2. Valentine B.A. Equine melanocytic tumors: a retrospective study of 53 horses (1988-1991). J. Vet Intern Med 1995, 9:291-297.
3. Johnson P.J. Dermatologic tumors (excluding sarcoids). Vet Clin North Am Equine Pract 1998, 14:625-658.
4. Smith S.H., Goldschmidt M.H., McManus P.M. A comparative review of melanocytic neoplasms. Vet Pathol 2002, 39:651-678.
5. Müller J., Feige K., Wunderlin P., Hödl A., Meli M.L., Seltenhammer M., et al. Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J Immunother 2011, 34:58-64.
6. Müller J.M., Wissemann J., Meli M.L., Dasen G., Lutz H., Heinzerling L., et al. In vivo induction of interferon gamma expression in grey horses with metastatic melanoma resulting from direct injection of plasmid DNA coding for equine interleukin 12. Schweiz Arch Tierheilkd 2011, 153:509-513.
7. Finocchiaro L.M., Riveros M.D., Glikin G.C. Cytokine-enhanced vaccine and suicide gene therapy as adjuvant treatments of metastatic melanoma in a horse. Vet Rec 2009, 164:278-279.
8. Tuthil R.J., Clark R.H., Levene A. Equine melanotic disease: a unique animal model for human dermal melanocytic disease. Lab Invest 1982, 46:85A.
9. Seltenhammer M.H., Heere-Ress E., Brandt S., Druml T., Jansen B., Pehamberger H., et al. Comparative histopathology of grey-horse melanoma and human malignant melanoma. Pigment Cell Res 2004, 17:674-681.
10. Comfort A. Coat-colour and longevity in thoroughbred mares. Nature 1985, 182:1531-1532.
11. Rieder S., Stricker C., Joerg H., Dummer R., Stranzinger G. A comparative genetic approach for the investigation of ageing grey horse melanoma. J Anim Breed Genet 2000, 117:73-82.
12. Fleury C., Bérard F., Leblond A., Faure C., Ganem N., Thomas L. The study of cutaneous melanomas in Camargue-type gray-skinned horses (2): epidemiological survey. Pigment Cell Res 2000, 13:47-51.
13. Seltenhammer M.H., Simhofer H., Scherzer S., Zechner R., Curik I., Sölkner J., et al. Equine melanoma in a population of 296 grey Lipizzaner horses. Equine Vet J 2003, 35:153-157.
14. Rosengren Pielberg G., Golovko A., Sundström E., Curik I., Lennartsson J., Seltenhammer M.H., et al. A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse. Nat Genet 2008, 40:1004-1009.
15. Sturm R.A., Duffy D.L., Box N.F., Chen W., Smit D.J., Brown D.L., et al. The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes. Pigment Cell Res 2003, 16:266-272.
16. Carlson J.A., Linette G.P., Aplin A., Slominski A. Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol Clin 2007, 25:541-557.
17. Williams P.F., Olsen C.M., Hayward N.K., Whiteman D.C. Melanocortin- 1-receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer 2011, 129:1730-1740.
18. Rieder S., Taourit S., Mariat D., Langlois B., Guérin G. Mutations in the agouti (ASIP), the extension (MC1R), and the brown (TYRP1) loci and their association to coat color phenotypes in horses (Equus caballus). Mamm Genome 2001, 12:450-455.
19. Smith A.G., Luk N., Newton R.A., Roberts D.W., Sturm R.A., Muscat G.E. Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells. J Biol Chem 2008, 283:12564-12570.
20. Zhao Z.Z., Duffy D.L., Thomas S.A., Martin N.G., Hayward N.K., Montgomery G.W. Polymorphisms in the syntaxin 17 gene are not associated with human cutaneous malignant melanoma. Melanoma Res 2009, 19:80-86.
21. Wang N., Hebert D. Tyrosinase maturation through the mammalian secretory pathway: bringing color to life. Pigment Cell Res 2006, 19:3-18.
22. Vourc'h-Jourdain M., Volteau C., Nguyen J.M., Khammari A., Dreno B. Melanoma gene expression and clinical course. Arch Dermatol Res 2009, 301:673-679.
23. Phillips J.C., Lembcke L.M., Noltenius C., Newman S., Blackford J.T., Grosenbaugh D.A., et al. Evaluation of tyrosinase expression in canine and equine melanocytic tumors. Am J Vet Res 2012, 73:272-278.
24. Gibbs P., Brady B.M., Robinson W.A. The genes and genetics of malignant melanoma. J Cutan Med Surg 2002, 6:229-235.
25. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogenic human tyrosinase: a phase I trial. Clin Cancer Res 2003, 9:1284-1290.
26. Meyer R.G., Britten C.M., Siepmann U., Petzold B., Sagban T.A., Lehr H.A., et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother 2005, 54:453-467.
27. Liao J.C., Gregor P., Wolchok J.D., Orlandi F., Craft D., Leung C., et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006, 21:6-8.
28. Goubier A., Fuhrmann L., Forest L., Cachet N., Evrad-Blanchard M., Juillard V., et al. Superiority of needle-free transdermal plasmid delivery for the induction of antigen-specific IFNgamma T cell responses in the dog. Vaccine 2008, 26:2186-2190.
29. Phillips JC, Blackford JT, Lembcke LM, Grosenbaugh DA, Leard TA. Evaluation of needle free injection devices for intramuscular vaccination in horses. J Equine Vet Sci [Epub ahead of print].
30. Madden T.L., Tatusov R.L., Zhang J. Applications of network BLAST server. Methods Enzymol 1996, 266:131-141.
31. Kammula U., Marincola F.M., Rosenberg S.A. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 2000, 92:1336-1344.
32. Housseau F., Lindsey K.R., Oberholtzer S.D., Gonzales M.I., Boutin P., Moorthy A.K., et al. Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients. J Immunol Methods 2002, 266:87-103.
33. Shapiro S.S., Wilk M.B. An analysis of variance test for normality (complete samples). Biometrica 1965, 52:591-611.
34. Snedecor G.H., Cochran W.G. Shortcut and non-parametric methods. Statistical Methods 1989, Iowa State University Press, Iowa. 8th ed.
35. Simes R.J. An improved Bonferroni procedure for multiple test of significance. Biometrica 1986, 73:751-754.
36. Heinzerling L.M., Feige K., Rieder S., Akens M.K., Dummer R., Stranzinger G., et al. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med 2001, 78:692-702.
37. Potebnya G., Symchych T., Lisovenko G. Xenogenic cancer vaccines. Exp Oncol 2010, 32:61-65.
38. Shankar G., Salgaller M.L. Immune monitoring of cancer patients undergoing experimental immunotherapy. Curr Opin Mol Ther 2000, 2:66-73.
39. Clay T.M., Hobeika A.C., Mosca P.J., Lyerly H.K., Moarse M.A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 2001, 7:1127-1135.
40. Nagorsen D., Scheibenbogen C., Thiel E., Keilholz U. Immunological monitoring of cancer vaccine therapy. Expert Opin Biol Ther 2004, 4:1677-1684.
41. Gerber J.D., Marron A.E., Bass E.P., Beckenhauer W.H. Effect of age and pregnancy on the antibody and cell-mediated immune responses of horses to equine herpesvirus 1. Can J Comp Med 1977, 41:471-478.
42. Morein B., Blomqvist G., Hu K. Immune responsiveness in the neonatal period. J Comp Pathol 2007, 137(suppl 1):S27-S31.
43. Jaanson N., Möll K., Kulla A., Ustav M. Identification of the immunodominant regions of the melanoma antigen tyrosinase by anti-tyrosinase monoclonal antibodies. Melanoma Res 2003, 13:473-482.